{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:20:06Z","timestamp":1775067606705,"version":"3.50.1"},"reference-count":26,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2015,7,1]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Lymphocyte-depleted classical Hodgkin lymphoma (LDCHL) is the rarest entity among the classical Hodgkin lymphoma (CHL) subtypes, accounting for &lt;1% of CHL cases in Western countries. Similarly, primary splenic Hodgkin lymphoma is a rare diagnosis among all cases of lymphomatous involvement of spleen. Representing a combination of these two rare entities is the primary splenic LDCHL, with only one case reported in the literature. Here, we report second case of primary splenic LDCHL with a unique presentation. The patient was a 60-year-old Caucasian HIV-negative woman with a history of extranodal pleuropulmonary marginal zone lymphoma (MZL) treated with rituximab who presented with new-onset splenomegaly. Splenectomy revealed large number of Hodgkin\/Reed\u2013Sternberg cells (CD15+, CD30+, PAX5+ and EBER+) with the background consisting of histiocytes and smaller number of lymphocytes and eosinophils. There was no evidence of nodal or other extranodal site involvement. Thus, in addition to being a very rare entity, this case also provides an additional point of interest: the disease arose in the backdrop of previous diagnosis of extranodal pleuropulmonary MZL successfully treated with rituximab. We discuss the potential implications.<\/jats:p>","DOI":"10.1136\/jclinpath-2015-203145","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T22:15:29Z","timestamp":1437430529000},"page":"947-950","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["EBV-related primary splenic lymphocyte-depleted classical Hodgkin lymphoma"],"prefix":"10.1136","volume":"68","author":[{"given":"Vishwas","family":"Parekh","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Peker","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,7,20]]},"reference":[{"key":"2025092501300500000_68.11.947.1","unstructured":"Swerdlow SH , Campo E , Harris NL , et al ., eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008."},{"key":"2025092501300500000_68.11.947.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21995"},{"key":"2025092501300500000_68.11.947.3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11459"},{"key":"2025092501300500000_68.11.947.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024109"},{"key":"2025092501300500000_68.11.947.5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196604)19:4<461::AID-CNCR2820190402>3.0.CO;2-X"},{"key":"2025092501300500000_68.11.947.6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#"},{"key":"2025092501300500000_68.11.947.7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19841015)54:8<1606::AID-CNCR2820540823>3.0.CO;2-5"},{"key":"2025092501300500000_68.11.947.8","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90432-8"},{"key":"2025092501300500000_68.11.947.9","doi-asserted-by":"publisher","DOI":"10.1007\/BF02483066"},{"key":"2025092501300500000_68.11.947.10","first-page":"184","article-title":"Isolated splenic lymphoma: an elusive preoperative diagnosis","volume":"19","author":"Singh","year":"2000","journal-title":"Indian J Gastroenterol"},{"key":"2025092501300500000_68.11.947.11","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057977"},{"key":"2025092501300500000_68.11.947.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00283.x"},{"key":"2025092501300500000_68.11.947.13","first-page":"435","article-title":"Primary Hodgkin's disease of spleen\u2013a case report","volume":"49","author":"Gupta","year":"2006","journal-title":"Indian J Pathol Microbiol"},{"key":"2025092501300500000_68.11.947.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2006.12.005"},{"key":"2025092501300500000_68.11.947.15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/ajcp\/94.4.453","article-title":"Primary splenic lymphocyte-depletion Hodgkin's disease","volume":"94","author":"Zellers","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"2025092501300500000_68.11.947.16","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198805001-00002"},{"key":"2025092501300500000_68.11.947.17","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.7.512"},{"key":"2025092501300500000_68.11.947.18","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.1999.17.10.3122","article-title":"Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation","volume":"17","author":"Rowlings","year":"1999","journal-title":"J Clin Oncol"},{"key":"2025092501300500000_68.11.947.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(97)80023-6"},{"key":"2025092501300500000_68.11.947.20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31828e6564"},{"key":"2025092501300500000_68.11.947.21","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011201)92:11<2739::AID-CNCR10121>3.0.CO;2-E"},{"key":"2025092501300500000_68.11.947.22","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920501)69:9<2337::AID-CNCR2820690923>3.0.CO;2-K"},{"key":"2025092501300500000_68.11.947.23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6691998"},{"key":"2025092501300500000_68.11.947.24","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.1998.16.4.1635","article-title":"Peripheral T-cell lymphoma after anti-CD20 antibody therapy","volume":"16","author":"Tetreault","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025092501300500000_68.11.947.25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.V93.7.2427","article-title":"Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [Letter]","volume":"93","author":"Micallef","year":"1999","journal-title":"Blood"},{"key":"2025092501300500000_68.11.947.26","doi-asserted-by":"crossref","unstructured":"Kilner MF , Merante S , Svec A . The development of peripheral T-cell lymphoma after successful treatment for diffuse large B-cell lymphoma in a patient with suspected adult onset immunodeficiency: more questions than answers? BMJ Case Rep Published Online: 16 Dec 2013. doi:10.1136\/bcr-2013-200079 doi:10.1136\/bcr-2013-200079","DOI":"10.1136\/bcr-2013-200079"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2015-203145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:31:42Z","timestamp":1758789102000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2015-203145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,20]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,19]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/jclinpath-2015-203145"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2015-203145","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,20]]}}}